未经检验的干细胞疗法在市场上停留的时间越长，那些使用历史被做为其安全性和有效性的证明的风险就越大。
The longer that unproven therapies stay on the market, the greater is the risk that a history of use can be framed as evidence of safety and efficacy.
因此，我们不能直接照搬国外方法来检验中国证券市场的有效性。
Therefore, we can't directly copy foreign test method to examine Chinese securities market efficiency.
利用这种方法，还对我国A股市场的弱有效性加以检验，发现我国A股市场弱有效性不成立。
By testing the weak efficiency of Chinese A-share market in this paper, the conclusion that Chinese A-share market not be weak efficiency is made.
应用推荐